Suheung Co., Ltd. (008490.KS)
KRW 12880.0
(-1.68%)
KRW 12880.0
(-1.68%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 516.66 Billion KRW | 13.13% |
| 2022 | 456.69 Billion KRW | 20.16% |
| 2021 | 380.08 Billion KRW | -2.29% |
| 2020 | 389 Billion KRW | 2.41% |
| 2019 | 379.86 Billion KRW | 14.79% |
| 2018 | 330.92 Billion KRW | 12.39% |
| 2017 | 294.44 Billion KRW | -1.01% |
| 2016 | 297.45 Billion KRW | 1.27% |
| 2015 | 293.71 Billion KRW | 15.67% |
| 2014 | 253.91 Billion KRW | 2.26% |
| 2013 | 248.31 Billion KRW | -6.83% |
| 2012 | 266.51 Billion KRW | 18.26% |
| 2011 | 225.36 Billion KRW | 37.37% |
| 2010 | 164.05 Billion KRW | 37.22% |
| 2009 | 119.55 Billion KRW | -9.27% |
| 2008 | 131.76 Billion KRW | 51.03% |
| 2007 | 87.24 Billion KRW | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 528.95 Billion KRW | 2.38% |
| 2024 Q2 | 539.12 Billion KRW | 1.92% |
| 2023 FY | 516.66 Billion KRW | 13.13% |
| 2023 Q4 | 516.66 Billion KRW | -3.38% |
| 2023 Q1 | 492.46 Billion KRW | 7.83% |
| 2023 Q3 | 534.73 Billion KRW | 3.81% |
| 2023 Q2 | 515.1 Billion KRW | 4.6% |
| 2022 Q1 | 439.26 Billion KRW | 15.57% |
| 2022 FY | 456.69 Billion KRW | 20.16% |
| 2022 Q4 | 456.69 Billion KRW | -3.27% |
| 2022 Q3 | 472.11 Billion KRW | 4.8% |
| 2022 Q2 | 450.5 Billion KRW | 2.56% |
| 2021 FY | 380.08 Billion KRW | -2.29% |
| 2021 Q1 | 413.13 Billion KRW | 6.2% |
| 2021 Q3 | 417.57 Billion KRW | 5.13% |
| 2021 Q4 | 380.08 Billion KRW | -8.98% |
| 2021 Q2 | 397.17 Billion KRW | -3.86% |
| 2020 Q3 | 411.35 Billion KRW | 1.16% |
| 2020 Q2 | 406.65 Billion KRW | 4.56% |
| 2020 Q1 | 388.92 Billion KRW | 2.39% |
| 2020 FY | 389 Billion KRW | 2.41% |
| 2020 Q4 | 389 Billion KRW | -5.43% |
| 2019 Q4 | 379.86 Billion KRW | -0.34% |
| 2019 FY | 379.86 Billion KRW | 14.79% |
| 2019 Q3 | 381.15 Billion KRW | -3.76% |
| 2019 Q2 | 396.05 Billion KRW | 11.61% |
| 2019 Q1 | 354.86 Billion KRW | 7.23% |
| 2018 FY | 330.92 Billion KRW | 12.39% |
| 2018 Q1 | 310.64 Billion KRW | 5.5% |
| 2018 Q2 | 322.72 Billion KRW | 3.89% |
| 2018 Q3 | 335.06 Billion KRW | 3.82% |
| 2018 Q4 | 330.92 Billion KRW | -1.23% |
| 2017 Q1 | 293.44 Billion KRW | -1.35% |
| 2017 FY | 294.44 Billion KRW | -1.01% |
| 2017 Q4 | 294.44 Billion KRW | -2.35% |
| 2017 Q3 | 301.53 Billion KRW | 2.15% |
| 2017 Q2 | 295.19 Billion KRW | 0.6% |
| 2016 FY | 297.45 Billion KRW | 1.27% |
| 2016 Q4 | 297.45 Billion KRW | 7.26% |
| 2016 Q2 | 292.86 Billion KRW | 0.95% |
| 2016 Q3 | 277.3 Billion KRW | -5.31% |
| 2016 Q1 | 290.11 Billion KRW | -1.23% |
| 2015 Q3 | 292.2 Billion KRW | 2.19% |
| 2015 Q4 | 293.71 Billion KRW | 0.52% |
| 2015 FY | 293.71 Billion KRW | 15.67% |
| 2015 Q2 | 285.95 Billion KRW | 11.48% |
| 2015 Q1 | 256.5 Billion KRW | 1.02% |
| 2014 Q2 | 255.8 Billion KRW | -0.96% |
| 2014 Q1 | 258.28 Billion KRW | 4.01% |
| 2014 Q3 | 258.29 Billion KRW | 0.97% |
| 2014 FY | 253.91 Billion KRW | 2.26% |
| 2014 Q4 | 253.91 Billion KRW | -1.69% |
| 2013 FY | 248.31 Billion KRW | -6.83% |
| 2013 Q4 | 248.31 Billion KRW | -0.06% |
| 2013 Q3 | 248.45 Billion KRW | -15.35% |
| 2013 Q2 | 293.5 Billion KRW | 3.68% |
| 2013 Q1 | 283.07 Billion KRW | 6.21% |
| 2012 Q1 | 201.84 Billion KRW | 0.0% |
| 2012 Q4 | 266.51 Billion KRW | 0.0% |
| 2012 FY | 266.51 Billion KRW | 18.26% |
| 2011 FY | 225.36 Billion KRW | 37.37% |
| 2011 Q3 | 152.02 Billion KRW | 7.6% |
| 2011 Q2 | 141.28 Billion KRW | 28.23% |
| 2011 Q1 | 110.17 Billion KRW | 0.0% |
| 2010 Q1 | 71.84 Billion KRW | 0.0% |
| 2010 Q3 | 81.12 Billion KRW | -3.13% |
| 2010 FY | 164.05 Billion KRW | 37.22% |
| 2010 Q2 | 83.74 Billion KRW | 16.55% |
| 2009 FY | 119.55 Billion KRW | -9.27% |
| 2009 Q3 | 57.93 Billion KRW | 9.95% |
| 2009 Q2 | 52.69 Billion KRW | -3.52% |
| 2009 Q1 | 54.62 Billion KRW | 0.0% |
| 2008 Q1 | 61.7 Billion KRW | 0.0% |
| 2008 FY | 131.76 Billion KRW | 51.03% |
| 2008 Q2 | 48.38 Billion KRW | -21.58% |
| 2008 Q3 | 48.71 Billion KRW | 0.68% |
| 2007 Q3 | 51.97 Billion KRW | 7.5% |
| 2007 Q1 | 44.13 Billion KRW | 0.0% |
| 2007 FY | 87.24 Billion KRW | 0.0% |
| 2007 Q2 | 48.35 Billion KRW | 9.57% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -563.605% |
| Dong-A Socio Holdings Co., Ltd. | 929.79 Billion KRW | 44.432% |
| Ildong Holdings Co., Ltd. | 707.09 Billion KRW | 26.931% |
| HANDOK Inc. | 449.7 Billion KRW | -14.89% |
| Kukje Pharma Co., Ltd. | 85.67 Billion KRW | -503.089% |
| Yuhan Corporation | 712.33 Billion KRW | 27.469% |
| Dong-A ST Co., Ltd. | 631.91 Billion KRW | 18.237% |
| SAMSUNG PHARM. Co., LTD. | 15.89 Billion KRW | -3150.615% |
| Hanmi Pharm. Co., Ltd. | 851.82 Billion KRW | 39.346% |
| Hanall Biopharma Co.,Ltd | 53.52 Billion KRW | -865.219% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -150.962% |
| Dong Sung Bio Pharm.Co.,Ltd. | 75.17 Billion KRW | -587.325% |
| MYUNGMOON Pharm co.,Ltd | 147.79 Billion KRW | -249.586% |
| Hana Pharm Co., Ltd. | 70.4 Billion KRW | -633.891% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -563.605% |
| Ilsung Pharmaceuticals Co., Ltd. | 36.43 Billion KRW | -1318.007% |
| REYON Pharmaceutical Co., Ltd. | 251.15 Billion KRW | -105.72% |
| Aprogen pharmaceuticals,Inc. | 220.7 Billion KRW | -134.099% |
| JW Holdings Corporation | 827.51 Billion KRW | 37.564% |
| Ildong Pharmaceutical Co., Ltd. | 436.99 Billion KRW | -18.232% |
| Chong Kun Dang Pharmaceutical Corp. | 586.79 Billion KRW | 11.951% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -36.109% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -551.524% |
| Hyundai Pharmaceutical Co., Ltd. | 69.96 Billion KRW | -638.439% |
| Samil Pharmaceutical Co.,Ltd | 242.85 Billion KRW | -112.75% |
| Jeil Pharmaceutical Co.,Ltd | 330.29 Billion KRW | -56.427% |
| Yuyu Pharma, Inc. | 77.85 Billion KRW | -563.605% |
| Kwang Dong Pharmaceutical Co., Ltd. | 490.01 Billion KRW | -5.439% |
| Daewoong pharmaceutical Co.,Ltd | 858.02 Billion KRW | 39.784% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -36.109% |
| Yuhan Corporation | 712.33 Billion KRW | 27.469% |
| Jeil Pharma Holdings Inc | 477.81 Billion KRW | -8.132% |
| Yungjin Pharm. Co., Ltd. | 136.96 Billion KRW | -277.217% |
| JW Pharmaceutical Corporation | 379.59 Billion KRW | -36.109% |
| Samjin Pharmaceuticals Co., Ltd. | 154.53 Billion KRW | -234.335% |
| Korea United Pharm Inc. | 89.96 Billion KRW | -474.297% |
| CKD Bio Corp. | 170.76 Billion KRW | -202.569% |
| Daewon Pharmaceutical Co., Ltd. | 243.73 Billion KRW | -111.981% |
| Dongwha Pharm.Co.,Ltd | 157.65 Billion KRW | -227.717% |
| Whan In Pharm Co.,Ltd. | 43.01 Billion KRW | -1101.02% |
| Shin Poong Pharm.Co.,Ltd. | 79.3 Billion KRW | -551.524% |
| Chong Kun Dang Holdings Corp. | 632.51 Billion KRW | 18.316% |
| Boryung Corporation | 373.1 Billion KRW | -38.477% |
| Bukwang Pharmaceutical Co., Ltd. | 208.19 Billion KRW | -148.163% |
| Ilyang Pharmaceutical Co.,Ltd | 205.87 Billion KRW | -150.962% |
| JW Lifescience Corporation | 96.44 Billion KRW | -435.723% |